A recent study has revealed a concerning trend: despite increased access to antiseizure medication in low- and middle-income countries, there's a growing concern about the safety of these prescriptions. The potential risks to unborn children are a stark reminder of the importance of informed medical practice.
Led by Dr. Adrienne Chan and Professor Ian Wong, the study analyzed antiseizure medication use across 73 countries over a decade. While the rise in prescriptions is a positive step towards improving access to essential neurological medicines, it's not without its controversies.
The most commonly prescribed antiseizure medication, valproate, has been linked to birth defects and neurodevelopmental issues in babies born to mothers who took the drug during pregnancy. These issues can range from spina bifida and cleft palate to intellectual, communication, behavioral, and memory disorders. Despite these known risks, valproate remains an "essential medicine" on the World Health Organization's (WHO) list.
Here's where it gets controversial: the WHO has issued guidance against prescribing valproate to women and girls of childbearing age due to the risks of birth defects. Yet, the study found that valproate continues to be prescribed more frequently in countries where newer, safer antiseizure drugs are less affordable or available.
And this is the part most people miss: the researchers emphasize the urgent need for global education to ensure healthcare professionals and patients are aware of the risks associated with valproate. In high-income countries, tighter regulations and pregnancy prevention programs have successfully reduced valproate use, but this isn't the case everywhere.
The WHO commissioned this study as part of its ongoing efforts to promote the safe and equitable use of essential neurological medicines worldwide. The study's findings highlight the importance of understanding prescription patterns within specific populations and evaluating safety measures in different regions.
Dr. Chan emphasizes, "Our findings show that while access to antiseizure medicines is expanding globally, offering hope to patients who previously had limited treatment options, the continued widespread use of valproate in certain regions is a cause for concern. We must urgently work towards a global alignment on safe prescribing practices and patient education to protect future generations."
What are your thoughts on this? Do you think enough is being done to ensure the safe use of antiseizure medications, especially in low- and middle-income countries? Feel free to share your opinions and insights in the comments below!
